WO2017216722A3 - Compositions antifongiques synergiques et leurs procédés - Google Patents

Compositions antifongiques synergiques et leurs procédés Download PDF

Info

Publication number
WO2017216722A3
WO2017216722A3 PCT/IB2017/053505 IB2017053505W WO2017216722A3 WO 2017216722 A3 WO2017216722 A3 WO 2017216722A3 IB 2017053505 W IB2017053505 W IB 2017053505W WO 2017216722 A3 WO2017216722 A3 WO 2017216722A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
antifungal compositions
antifungal
synergistic antifungal
fungal infections
Prior art date
Application number
PCT/IB2017/053505
Other languages
English (en)
Other versions
WO2017216722A2 (fr
Inventor
Shamik GHOSH
Sumana GHOSH
Mau SINHA
Suresh SADHASIVAM
Anubhuti JAIN
Anamika BHATTACHARYYA
Original Assignee
Vyome Biosciences Pvt. Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AU2017283785A priority Critical patent/AU2017283785A1/en
Priority to US16/309,751 priority patent/US20190142800A1/en
Priority to EA201990025A priority patent/EA201990025A1/ru
Priority to BR112018075998-8A priority patent/BR112018075998A2/pt
Priority to KR1020197001063A priority patent/KR20190037229A/ko
Priority to JP2018566346A priority patent/JP2019521993A/ja
Application filed by Vyome Biosciences Pvt. Ltd. filed Critical Vyome Biosciences Pvt. Ltd.
Priority to MX2018015475A priority patent/MX2018015475A/es
Priority to CN201780049586.2A priority patent/CN109689034A/zh
Priority to EP17742542.8A priority patent/EP3468544A2/fr
Publication of WO2017216722A2 publication Critical patent/WO2017216722A2/fr
Publication of WO2017216722A3 publication Critical patent/WO2017216722A3/fr
Priority to PH12018550205A priority patent/PH12018550205A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin

Abstract

La présente invention concerne le domaine des antimicrobiens et des sciences pharmaceutiques. L'invention concerne des compositions antifongiques destinées à la gestion de la croissance fongique et au traitement d'infections fongiques, y compris le traitement d'infections fongiques résistantes. Les présentes compositions comprennent au moins un agent antifongique et au moins un acide gras saturé ou insaturé à chaîne moyenne ayant une longueur de chaîne carbonée de C-1 à C-14 ou un ester de celui-ci, éventuellement avec un ou des excipient(s), ce qui donne lieu à une activité antifongique synergique.
PCT/IB2017/053505 2016-06-13 2017-06-13 Compositions antifongiques synergiques et leurs procédés WO2017216722A2 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
US16/309,751 US20190142800A1 (en) 2016-06-13 2017-06-13 Synergistic antifungal compositions and methods thereof
EA201990025A EA201990025A1 (ru) 2017-02-17 2017-06-13 Синергические противогрибковые композиции и способы их приготовления
BR112018075998-8A BR112018075998A2 (pt) 2016-06-13 2017-06-13 composições antifúngicas sinérgicas e métodos das mesmas
KR1020197001063A KR20190037229A (ko) 2016-06-13 2017-06-13 상승효과적 항진균 조성물 및 그의 방법
JP2018566346A JP2019521993A (ja) 2016-06-13 2017-06-13 相乗的な抗真菌組成物及びその方法
AU2017283785A AU2017283785A1 (en) 2016-06-13 2017-06-13 Synergistic antifungal compositions and methods thereof
MX2018015475A MX2018015475A (es) 2016-06-13 2017-06-13 Composiciones antifungicas sinérgicas y métodos de las mismas.
CN201780049586.2A CN109689034A (zh) 2016-06-13 2017-06-13 协同抗真菌组合物及其方法
EP17742542.8A EP3468544A2 (fr) 2016-06-13 2017-06-13 Compositions antifongiques synergiques et leurs procédés
PH12018550205A PH12018550205A1 (en) 2016-06-13 2018-12-12 Synergistic antifungal compositions and methods thereof

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662349438P 2016-06-13 2016-06-13
US62/349,438 2016-06-13
IN201611027707 2016-08-12
IN201611027707 2016-08-12
IN201711005689 2017-02-17
IN201711005689 2017-02-17

Publications (2)

Publication Number Publication Date
WO2017216722A2 WO2017216722A2 (fr) 2017-12-21
WO2017216722A3 true WO2017216722A3 (fr) 2018-03-01

Family

ID=60663501

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2017/053505 WO2017216722A2 (fr) 2016-06-13 2017-06-13 Compositions antifongiques synergiques et leurs procédés

Country Status (1)

Country Link
WO (1) WO2017216722A2 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10070649B2 (en) 2013-01-30 2018-09-11 Agrofresh Inc. Volatile applications against pathogens
US11039617B2 (en) 2013-01-30 2021-06-22 Agrofresh Inc. Large scale methods of uniformly coating packaging surfaces with a volatile antimicrobial to preserve food freshness
TW201735792A (zh) 2016-03-07 2017-10-16 農業保鮮股份有限公司 使用苯并氧雜硼雜環戊烯化合物和防腐氣體作為作物的抗微生物劑之協同方法
EP3538079A4 (fr) 2016-11-28 2020-03-04 Cellix Bio Private Limited Compositions et méthodes pour le traitement de maladies infectieuses buccales
US20200237705A1 (en) * 2017-10-16 2020-07-30 Hennepin Life Sciences, Llc Method to treat antimicrobial resistant candida
KR102098728B1 (ko) * 2018-07-18 2020-04-08 강현준 카프릴산을 포함하는 닭진드기 살충용 조성물
WO2020061709A1 (fr) 2018-09-27 2020-04-02 0903608 B.C. Ltd. Compositions pesticides agissant en synergie et procédés d'administration d'ingrédients actifs insecticides
CA3114030A1 (fr) * 2018-09-27 2020-04-02 0903608 B.C. Ltd. Compositions pesticides synergiques et procedes d'apport d'agents actifs
WO2020193679A1 (fr) 2019-03-28 2020-10-01 Dsm Ip Assets B.V. Protection de culture contre une infection fongique
FR3094636B1 (fr) * 2019-04-05 2022-07-29 Soc Dexploitation De Produits Pour Les Industries Chimiques Seppic Composition pharmaceutique à usage topique comprenant au moins une substance antifongique locale azolée
US10898470B1 (en) 2019-08-13 2021-01-26 Sato Pharmaceutical Co., Ltd. Pharmaceutical composition containing antifungal agent as active ingredient
KR20210032662A (ko) * 2019-09-17 2021-03-25 주식회사 바이오빌리프 킬레이트화제를 포함하는 안정화된 에피나코나졸-함유 약학 조성물
CN110683992B (zh) * 2019-11-01 2021-02-26 徐州工业职业技术学院 一种一锅法合成硝酸益康唑的方法
JP2023521284A (ja) * 2020-03-06 2023-05-24 ユニリーバー・アイピー・ホールディングス・ベスローテン・ヴェンノーツハップ パーソナルケア組成物及び方法
CN113797114A (zh) 2020-06-12 2021-12-17 玫琳凯有限公司 局部用组合物和方法
WO2022101235A1 (fr) 2020-11-13 2022-05-19 Unilever Ip Holdings B.V. Composition de nettoyage à activité antimicrobienne
CN113143981B (zh) * 2021-05-20 2022-11-18 郭良君 油松叶提取物协同氟康唑在制备抗真菌药物中的应用
FR3124080A1 (fr) * 2021-06-21 2022-12-23 Evergreen Land Limited Formulation topique antimicrobienne

Citations (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0457333A2 (fr) * 1990-05-17 1991-11-21 Bristol-Myers Squibb Company Composition pour l'application topique
FR2685867A1 (fr) * 1992-01-07 1993-07-09 Thorel Jean Compositions contre la desquamation de l'epiderme et du cuir chevelu.
WO1993020812A1 (fr) * 1992-04-14 1993-10-28 Bioglan Ab Potentialisation d'effets antimicrobiens
WO1996039131A1 (fr) * 1995-06-06 1996-12-12 Knowles W Roy Composition de traitement local de mycoses
JPH09110693A (ja) * 1995-08-10 1997-04-28 Taisho Pharmaceut Co Ltd 抗真菌剤
US6162834A (en) * 1995-04-25 2000-12-19 L'oreal Foaming oil-in-water emulsion based on nonionic surfactants, a fatty phase and a crosslinked cationic or anionic polymer, and its use in topical applications
WO2001043706A1 (fr) * 1999-12-18 2001-06-21 Cognis Deutschland Gmbh & Co. Kg Utilisation d"agents antipelliculaires nanometriques
US20010046478A1 (en) * 2000-03-09 2001-11-29 Manfred Bohn Antiinfective combinations and their use for the topical treatment of fungal infections of the toenails and fingernails
WO2003017986A1 (fr) * 2001-08-27 2003-03-06 Won Jin Biopharma Co., Ltd. Compositions contenant de l'itraconazole et leurs procedes de preparation
US20030158126A1 (en) * 2002-02-06 2003-08-21 Khanuja Suman Preet Singh Method of treatment for fungal infections with a synergistic formulation of antifungal agents
US20030185915A1 (en) * 2002-03-28 2003-10-02 Jaime Carlo Synergetic composition for the treatment of psoriasis and other skin disorders and method therefor
JP2004025161A (ja) * 2002-05-02 2004-01-29 Kurita Water Ind Ltd 汚泥脱水ケーキの臭気抑制方法及び臭気抑制剤
US20040101538A1 (en) * 2001-03-30 2004-05-27 Catherine Larnier Topical composition
WO2005053613A2 (fr) * 2003-11-26 2005-06-16 Combinatorx, Inc. Combinaisons de traitement d'infections fongiques
JP2006124312A (ja) * 2004-10-28 2006-05-18 Lion Corp シャンプー組成物
US20070078116A1 (en) * 2003-08-20 2007-04-05 Fairfield Clinical Trials, Llc Method of treatment of otitis externa
KR100801324B1 (ko) * 2005-04-21 2008-03-03 주식회사 나노스페이스 아연 피리치온 수용성 또는 수분산 콜로이드 조성물 및 그제조방법
US20080075745A1 (en) * 2006-09-21 2008-03-27 Glenmark Pharmaceuticals Limited Topical pharmaceutical compositions containing ciclopirox or a pharmaceutically acceptable salt thereof
US20090202596A1 (en) * 2006-06-13 2009-08-13 Farmatron Limited Pharmaceutical compositions with biological barriers permeation enhancing properties
WO2009147144A2 (fr) * 2008-06-02 2009-12-10 Intervet International B.V. Composition comprenant un antibiotique et un corticostéroïde
WO2010108060A1 (fr) * 2009-03-20 2010-09-23 Stiefel Laboratories, Inc. Compositions de monoglycérides d'acides gras
CN101919807A (zh) * 2010-07-16 2010-12-22 钟术光 栓剂组合物
WO2011014850A2 (fr) * 2009-07-31 2011-02-03 Nuvo Research Inc. Formulations à usage topique à base d'un eutectique
US20120101135A1 (en) * 2009-05-23 2012-04-26 Clariant Finance (Bvi) Limited Composition containing sorbitan monocaprylate and antimicrobial substances
WO2012072424A2 (fr) * 2010-12-02 2012-06-07 Unilever Plc Shampooing antipelliculaire
DE102011119033A1 (de) * 2011-11-22 2012-09-06 Clariant International Ltd. Verwendung von Isosorbidcaprylaten/capraten in Deodorantien und Antiperspirantien
US20120309843A1 (en) * 2009-12-23 2012-12-06 Nuvo Research Inc. Highly permeating terbinafine formulation
WO2013017259A1 (fr) * 2011-08-04 2013-02-07 Clariant International Ltd Compositions contenant du monoester d'isorsorbide et des n-hydroxypyridones
WO2013093823A2 (fr) * 2011-12-20 2013-06-27 Vyome Biosciences Pvt Ltd Compositions d'huile à usage topique pour le traitement des infections fongiques
CN103719103A (zh) * 2010-12-07 2014-04-16 陕西韦尔奇作物保护有限公司 一种含有粉唑醇的杀菌组合物
WO2014167554A2 (fr) * 2013-04-12 2014-10-16 Vyome Biosciences Pvt. Ltd. Composition et formulation d'agents antimicrobiens, procédés correspondants et méthodes pour le traitement d'infections microbiennes
WO2014195872A1 (fr) * 2013-06-04 2014-12-11 Vyome Biosciences Pvt. Ltd. Particules enrobées et compositions les comprenant
CN104548100A (zh) * 2015-01-13 2015-04-29 北京北大明德科技发展有限公司 一种外用治疗皮肤病的组合物
CN105193808A (zh) * 2015-10-14 2015-12-30 南京邮电大学 Bdsf与伊曲康唑联用对临床耐药白念珠菌的协同药效
US20160015615A1 (en) * 2013-03-11 2016-01-21 Beiersdorf Ag Combinations of alkylamidothiazoles and preservatives
WO2017203456A1 (fr) * 2016-05-25 2017-11-30 Glenmark Pharmaceuticals Limited Compositions topiques stables de luliconazole

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5624666A (en) 1995-01-20 1997-04-29 The Procter & Gamble Company Anti-dandruff shampoos with particulate active agent and cationic polymer
BRPI0713209A2 (pt) 2006-07-07 2012-03-20 Unilever N.V composição de condicionamento de cabelos e método de mitigar caspa

Patent Citations (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0457333A2 (fr) * 1990-05-17 1991-11-21 Bristol-Myers Squibb Company Composition pour l'application topique
FR2685867A1 (fr) * 1992-01-07 1993-07-09 Thorel Jean Compositions contre la desquamation de l'epiderme et du cuir chevelu.
WO1993020812A1 (fr) * 1992-04-14 1993-10-28 Bioglan Ab Potentialisation d'effets antimicrobiens
US6162834A (en) * 1995-04-25 2000-12-19 L'oreal Foaming oil-in-water emulsion based on nonionic surfactants, a fatty phase and a crosslinked cationic or anionic polymer, and its use in topical applications
WO1996039131A1 (fr) * 1995-06-06 1996-12-12 Knowles W Roy Composition de traitement local de mycoses
JPH09110693A (ja) * 1995-08-10 1997-04-28 Taisho Pharmaceut Co Ltd 抗真菌剤
WO2001043706A1 (fr) * 1999-12-18 2001-06-21 Cognis Deutschland Gmbh & Co. Kg Utilisation d"agents antipelliculaires nanometriques
US20010046478A1 (en) * 2000-03-09 2001-11-29 Manfred Bohn Antiinfective combinations and their use for the topical treatment of fungal infections of the toenails and fingernails
US20040101538A1 (en) * 2001-03-30 2004-05-27 Catherine Larnier Topical composition
WO2003017986A1 (fr) * 2001-08-27 2003-03-06 Won Jin Biopharma Co., Ltd. Compositions contenant de l'itraconazole et leurs procedes de preparation
US20030158126A1 (en) * 2002-02-06 2003-08-21 Khanuja Suman Preet Singh Method of treatment for fungal infections with a synergistic formulation of antifungal agents
US20030185915A1 (en) * 2002-03-28 2003-10-02 Jaime Carlo Synergetic composition for the treatment of psoriasis and other skin disorders and method therefor
JP2004025161A (ja) * 2002-05-02 2004-01-29 Kurita Water Ind Ltd 汚泥脱水ケーキの臭気抑制方法及び臭気抑制剤
US20070078116A1 (en) * 2003-08-20 2007-04-05 Fairfield Clinical Trials, Llc Method of treatment of otitis externa
WO2005053613A2 (fr) * 2003-11-26 2005-06-16 Combinatorx, Inc. Combinaisons de traitement d'infections fongiques
JP2006124312A (ja) * 2004-10-28 2006-05-18 Lion Corp シャンプー組成物
KR100801324B1 (ko) * 2005-04-21 2008-03-03 주식회사 나노스페이스 아연 피리치온 수용성 또는 수분산 콜로이드 조성물 및 그제조방법
US20090202596A1 (en) * 2006-06-13 2009-08-13 Farmatron Limited Pharmaceutical compositions with biological barriers permeation enhancing properties
US20080075745A1 (en) * 2006-09-21 2008-03-27 Glenmark Pharmaceuticals Limited Topical pharmaceutical compositions containing ciclopirox or a pharmaceutically acceptable salt thereof
WO2009147144A2 (fr) * 2008-06-02 2009-12-10 Intervet International B.V. Composition comprenant un antibiotique et un corticostéroïde
WO2010108060A1 (fr) * 2009-03-20 2010-09-23 Stiefel Laboratories, Inc. Compositions de monoglycérides d'acides gras
US20120101135A1 (en) * 2009-05-23 2012-04-26 Clariant Finance (Bvi) Limited Composition containing sorbitan monocaprylate and antimicrobial substances
WO2011014850A2 (fr) * 2009-07-31 2011-02-03 Nuvo Research Inc. Formulations à usage topique à base d'un eutectique
US20120309843A1 (en) * 2009-12-23 2012-12-06 Nuvo Research Inc. Highly permeating terbinafine formulation
CN101919807A (zh) * 2010-07-16 2010-12-22 钟术光 栓剂组合物
WO2012072424A2 (fr) * 2010-12-02 2012-06-07 Unilever Plc Shampooing antipelliculaire
CN103719103A (zh) * 2010-12-07 2014-04-16 陕西韦尔奇作物保护有限公司 一种含有粉唑醇的杀菌组合物
WO2013017259A1 (fr) * 2011-08-04 2013-02-07 Clariant International Ltd Compositions contenant du monoester d'isorsorbide et des n-hydroxypyridones
DE102011119033A1 (de) * 2011-11-22 2012-09-06 Clariant International Ltd. Verwendung von Isosorbidcaprylaten/capraten in Deodorantien und Antiperspirantien
WO2013093823A2 (fr) * 2011-12-20 2013-06-27 Vyome Biosciences Pvt Ltd Compositions d'huile à usage topique pour le traitement des infections fongiques
US20160015615A1 (en) * 2013-03-11 2016-01-21 Beiersdorf Ag Combinations of alkylamidothiazoles and preservatives
WO2014167554A2 (fr) * 2013-04-12 2014-10-16 Vyome Biosciences Pvt. Ltd. Composition et formulation d'agents antimicrobiens, procédés correspondants et méthodes pour le traitement d'infections microbiennes
WO2014195872A1 (fr) * 2013-06-04 2014-12-11 Vyome Biosciences Pvt. Ltd. Particules enrobées et compositions les comprenant
CN104548100A (zh) * 2015-01-13 2015-04-29 北京北大明德科技发展有限公司 一种外用治疗皮肤病的组合物
CN105193808A (zh) * 2015-10-14 2015-12-30 南京邮电大学 Bdsf与伊曲康唑联用对临床耐药白念珠菌的协同药效
WO2017203456A1 (fr) * 2016-05-25 2017-11-30 Glenmark Pharmaceuticals Limited Compositions topiques stables de luliconazole

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
- ANONYMOUS: "Safety data sheet of BDSF", 1 January 2015 (2015-01-01), XP055407957, Retrieved from the Internet <URL:http://www.abcam.com/ps/Products/145/ab145341/Msds/ab145341_CLP1_EN.pdf> [retrieved on 20170919] *
ANONYMOUS: "BDSF (cis-2-dodecenoic acid) | Abcam", 1 January 2017 (2017-01-01), XP055407954, Retrieved from the Internet <URL:http://www.abcam.com/bdsf-cis-2-dodecenoic-acid-ab145341.html> [retrieved on 20170919] *
CATARINA COSTA ET AL: "The dual role of candida glabrata drug:H+ antiporter CgAqr1 (ORF CAGL0J09944g) in antifungal drug and acetic acid resistance", FRONTIERS IN MICROBIOLOGY, vol. 4, 1 January 2013 (2013-01-01), XP055437744, DOI: 10.3389/fmicb.2013.00170 *
VIKTOR ALEXANDER CZAIKA ET AL: "Trichophyton mentagrophytes cause underestimated contagious zoophilic fungal infection", MYCOSES, vol. 56, 10 April 2013 (2013-04-10), GB, pages 33 - 37, XP055436429, ISSN: 0933-7407, DOI: 10.1111/myc.12069 *
YINYUE DENG ET AL: "Cis-2-dodecenoic acid signal modulates virulence of Pseudomonas aeruginosa through interference with quorum sensing systems and T3SS", BMC MICROBIOLOGY, BIOMED CENTRAL LTD, GB, vol. 13, no. 1, 18 October 2013 (2013-10-18), pages 231, XP021163241, ISSN: 1471-2180, DOI: 10.1186/1471-2180-13-231 *

Also Published As

Publication number Publication date
WO2017216722A2 (fr) 2017-12-21

Similar Documents

Publication Publication Date Title
WO2017216722A3 (fr) Compositions antifongiques synergiques et leurs procédés
PH12018550205A1 (en) Synergistic antifungal compositions and methods thereof
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
WO2016131067A3 (fr) Compositions pharmaceutiques contenant du méloxicam
EP3895717A4 (fr) Composition pharmaceutique pour prévenir ou traiter un cancer, comprenant weissella cibaria wikim28 en tant que substance active
AR102973A1 (es) Uso del compuesto 3,5-dihidroxi-4-isopropil-trans-estilbeno para la preparación de una composición farmacéutica, dicho compuesto y composición farmacéutica que lo comprende
BR112018005905A2 (pt) ?composto, composição farmacêutica, métodos para evitar ou tratar uma doença ou condição, lesões de órgão, hepatotoxicidade e fígado gorduroso, e, uso de um composto?
WO2016142224A8 (fr) Mélanges fongicides contenant des fongicides de type strobilurine
GT201700124A (es) Formulación de relación fija de insulina glargina/lixisenatida
CL2019003113A1 (es) Uso de un compuesto de picolinamida acílica como fungicida para el control de hongos fitopatogénicos en cultivos de fila.
UY37306A (es) Combinaciones de compuestos activos
CL2016002879A1 (es) Composiciones farmacéuticas para tratar enfermedades infecciosas
WO2015112902A3 (fr) Inhibiteurs de cystathionine- (gamma)-lyase (cse) pour le traitement de la douleur
WO2015066302A3 (fr) Compositions, méthodes d&#39;utilisation et méthodes de traitement
EP3352750A4 (fr) Dérivé de cyclohexène, son procédé de préparation et composition pharmaceutique pour prévenir ou traiter une maladie métabolique, contenant ledit dérivé comme principe actif
EP3539978A4 (fr) Fragment de nkx3.2 et composition pharmaceutique le comprenant en tant que principe actif
MX2016010699A (es) Composiciones y metodos para tratar neutropenia.
ZA202006341B (en) Synergistic formulation including at least one gibberellin compound and salicyclic acid
MX2019001771A (es) Composición farmacéutica sólida que comprende el sofosbuvir amorfo.
WO2017030383A3 (fr) Composition pharmaceutique pour prévenir ou traiter une dystrophie musculaire, contenant du bakuchiol en tant que principe actif
BR112017024126B8 (pt) Composições farmacêuticas, composto a micronizado e/ou pelo menos um sal farmaceuticamente aceitável micronizado do composto a e uso dos mesmos
EA201692493A8 (ru) Противомикробные фармацевтические композиции со способностями ингибирования множественной лекарственной устойчивости
WO2016149382A3 (fr) Compositions et procédés de suppression ou de réduction de la réponse immunitaire systémique chez un sujet
JOP20180071A1 (ar) استخدام مشتقات أمينو ألكيل بنزوثيازبين
AR103636A1 (es) Métodos de tratamiento de neuralgia postherpética con una formulación tópica de un compuesto de espiro-oxindol

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17742542

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2018566346

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112018075998

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 20197001063

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2017742542

Country of ref document: EP

Effective date: 20190114

ENP Entry into the national phase

Ref document number: 2017283785

Country of ref document: AU

Date of ref document: 20170613

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 112018075998

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20181213